Market revenue in 2023 | USD 179.6 million |
Market revenue in 2030 | USD 412.5 million |
Growth rate | 12.6% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.91% in 2023. Horizon Databook has segmented the Spain immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Spanish institutes such as the International University of Catalunya and CIBERNED are actively involved in investigating Alzheimer’s disease biomarkers, which can potentially be used to detect the disease at an early stage.
For instance, in March 2019, the Multiple Sclerosis Center of Catalonia (Cemcat) acquired a fully automated ultrasensitive analyzer for the identification of neurological biomarkers. This analyzer used state-of-the-art technology SIMOA HD-1 to detect proteins with a sensitivity up to 1,000 higher than traditional immunoassays.
In addition, economic development is likely to have a positive impact on affordability and consequent market penetration of neurological biomarkers. Early & accurate diagnosis and timely treatment would aid in reducing disease burden and mortality rate.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Spain immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account